The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.
CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback